IPF in Untreated Patients Detected with 86% Accuracy in a Single NuQ Blood Test, Company Reports
VolitionRx recently reported preliminary results from a pilot study showing that its NuQ blood assay was capable of detecting 86 percent of relevant idiopathic pulmonary fibrosis (IPF) cases among the 78 participants of a clinical trial at Liège University Hospital. The NuQ test utilizes the company’s proprietary Nucleosomics technology platform, which identifies and measures circulating fragments…